November 5, 2002

Johnson & Johnson Wound Management Worldwide Introduces SURGIFOAM Absorbable Gelatin Powder

SOMERVILLE, N.J., Nov 5, 2002 /PRNewswire-FirstCall via COMTEX/ --

Johnson & Johnson Wound Management today announced the introduction of SURGIFOAM* Absorbable Gelatin Powder for hemostasis in selected applications when control of capillary, venous and arteriolar bleeding by pressure, ligature and other conventional procedures is ineffective or impractical. SURGIFOAM Absorbable Gelatin Powder is the newest addition to the world's most complete line of absorbable hemostats.

SURGIFOAM Powder is made from the same safe, absorbable porcine gelatin that is used in SURGIFOAM* Gelatin Sponge, which has been used safely and effectively more than 100 million times. When mixed with sterile saline, SURGIFOAM Powder forms a paste that can be spread or shaped to conform to irregular surfaces to stop bleeding fast.

"In spinal surgery, effective hemostasis is critically important," says Nathan Lebwohl, M.D., a spinal surgeon at the University of Miami Spine Institute. "When working in the spinal canal, bleeding can obscure visualization, making surgical treatment difficult. SURGIFOAM Powder stops the bleeding quickly, allowing the surgeon to continue working. It is fast, effective and easy to use."

SURGIFOAM is the first and only hemostatic powder that comes in its own self-contained, sterile mixing vessel. The container keeps the product ready for mixing and minimizes powder clumping and fly-away. It is ready to use in four steps: open the sterile container, add three to four milliliters of sterile saline, then reattach the lid and shake or stir.

SURGIFOAM Powder should not be used in closure of skin incisions, or in patients with known allergies to porcine gelatin.

Johnson & Johnson Wound Management, a division of ETHICON, INC., a Johnson & Johnson company, continues Johnson & Johnson's 100-year commitment to skin and wound care today with inventive products for chronic and acute wound management, burn care and hemostasis. For more information about Johnson & Johnson Wound Management or other ETHICON divisions, call 877-384-4266 in the United States or visit http://www.jnjgateway.com/hemostasis or http://www.ethiconinc.com.

     *Trademark
                     Make Your Opinion Count - Click Here
               http://tbutton.prnewswire.com/prn/11690X75068506

SOURCE Ethicon, Inc.

Amy Firsching, +1-908-218-2783, or afirschi@ethus.jnj.com, for
Ethicon, Inc.
http://www.ethiconinc.com

News Provided by COMTEX


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.